Stemmer Imaging AG STEMMER IMAGIN.../ DE000A2G9MZ9 /
| 5/24/2024 4:19:37 PM | Chg. - | Volume | Bid6:00:08 AM | Ask6:00:08 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 33.30EUR | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | 224.9 mill.EUR | 2.17% | 21.49 |
GlobeNewswire
12/8/2023
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire
12/21/2021
illumiSonics Inc. Expands Its Executive Management With the Appointment of Jochen Schweizer as Chief...
GlobeNewswire
4/13/2021
Effective Digital Customer Engagement is Mission Critical but also Challenging to Achieve, Concludes...
GlobeNewswire
1/17/2018
World Spectral Imaging End-User Needs, Markets and Trends, 2022 - Industry 4.0, Sustainable Food Pro...
GlobeNewswire
8/24/2017
Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally ad...
GlobeNewswire
6/23/2017
Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- ...
GlobeNewswire
6/2/2017
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus ...
GlobeNewswire
4/10/2017
CORRECTION: MPI - Notice to convene Ordinary Annual General Meeting CORRECTION
GlobeNewswire
2/10/2017
Kitov Announces Settlement Agreement with Minority Shareholder of Recently Acquired TyrNovo
GlobeNewswire
12/9/2016
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of pati...
GlobeNewswire
11/1/2016
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advan...
GlobeNewswire
10/8/2016
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival ...
GlobeNewswire
11/4/2015
Payoneer Selected by Amazon to Expand Cross-Border Payment Options in Select Countries
